close
Sunday December 22, 2024

Weight loss obsession: Taking Ozempic allegedly leads to woman's death

Most of the people who have put on a lot of weight are trying to find ways through which they can reduce a few pounds, but a woman's bid to do that took her life

By Web Desk
November 09, 2023
Trish Webster (right) was taking Ozempic to lose weight for her daughters wedding. — 60 Minutes Australia
Trish Webster (right) was taking Ozempic to lose weight for her daughter's wedding. — 60 Minutes Australia

Most of the people who have put on a lot of weight are trying to find ways through which they can reduce a few pounds, but a woman's bid to do that took her life.

An Australian woman lost her life after allegedly taking prescribed Ozempic to shed weight for her daughter's wedding, The Independent reported.

The 56-year-old Trish Webster was taking Ozempic, which is one of many drugs named GLP-1s. They are used to treat type 2 diabetes. However, some of them have been FDA-sanctioned to treat chronic weight management.

Ozempic has become a thing on social media as people are taking the drug after it was either rumoured or confirmed that influencers and celebrities were taking it to control their weight.

The drug mimics the natural hormone GLP-1 by sending signals to a person's brain that they are full — even if they aren't.

In an interview with 60 Minutes Australia, Trish’s husband Roy Webster said his wife saw the ad for Ozempic on the television and got a prescription from a doctor.

The 56-year-old was trying to shed weight by exercising and dieting, but it wasn't as effective. She wanted to drop a few kilos before her daughter's big day.

"My daughter was getting married, and she just kept mentioning that dress that she wanted to wear," Mr Webster recalled to the TV show.

"She went to the dressmaker to get the measurements. It was one big nightmare from there."

Trish lost 16 kilogrammes altogether in three months, but that came at the cost of her life.

The manufacturer of Ozempic, Novo Nordisk, claimed that reports of ileus emerged after the drug was already in circulation, suggesting a lack of prior awareness of the risk.